Calidi Biotherapeutics (NYSE American: CLDI) is developing a precision genetic medicine platform for cancer treatment. The company's innovative approach focuses on using engineered viruses to deliver genetic medicines that can target both primary tumors and metastatic sites.
The development comes amid concerning cancer statistics, with 20 million annual cancer diagnoses globally and projections showing this number could reach 35 million by 2050. Currently, cancer claims nearly 10 million lives annually worldwide, highlighting the urgent need for more effective treatment options.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.